exercise, approximately corresponding to the first ventilatory threshold (VT) 6, 7 . It can be 23 performed early after a myocardial infarction (MI) 8 , and can be used to assess cardiac 24 rehabilitation programs 9 , 10 . 25
The 200-Meter Fast Walk Test (200MFWT) has recently been developed in healthy 26 elderly people and in CAD patients 7, 11 . It has also been used to assess improvements in 27 functional capacity after a training program in elderly 12 and CAD patients 7 . The 200MFWT 28 explores higher exercise intensities than does the 6MWT, both of which could be of interest 29 in cardiac rehabilitation. Indeed, recent studies suggest that vigorous exercise training and/or 30 high intensity aerobic interval exercise may be superior to moderate intensity exercise in that 31 they increase aerobic capacity to a greater extend in CAD patients 13, 14 . 32
Field walk tests are objective measures that provide a means to monitor response to 33 treatment 3 . The interpretation of functional changes can guide clinical management and can 34 be primary endpoints in interventional or observational studies. It is thus important to 35 determine whether a change in function is clinically relevant or not. One method to answer 36 this question quantitatively is to determine the minimal clinically important difference 37 (MCID) for the test used. 38
The Minimal Clinically Important Difference (MCID) is a concept defined as "the smallest 39 difference in score in the domain of interest which patients perceive as beneficial and which 40 would mandate, in the absence of troublesome side effects and excessive cost, a change in the 41 patients management" 15 . The MCID is different from the Minimal Detectable Change, that 42 indicates the amount of change required to exceed measurement variability 16, 17 . Indeed, 43 when interpreting clinical measures, it is important to consider that, even though small 44 changes may be statistically significant, they may not be clinically relevant 16, 18 . MCID 45 values are therefore important to appreciate the clinical relevance of observed changes, at 46 hal-00702219, version 1 -4 Jun 2012 both the individual and group levels. As individuals interpret "meaningful change" 47 differently, depending on a multitude of factors (e.g. prior level of function, age, physical 48 environment ), the MCID is a dynamic and context-specific concept, and derivations of the 49 MCID are usually estimated only for a specific population at a particular stage of recovery 19 . 50
Because estimation of the MCID is a process evolving from multiple perspectives, it is 51 important to estimate the MCID for key clinical outcome measures, such as walking ability in 52 CAD patients. Indeed, walking is one of the most basic human motor activities and plays a 53 key role in patients' participation. 54
Numerous methods to derive the MCID have been described 15, 16, [20] [21] [22] [23] . They are 55 usually divided into 2 categories: distribution-based and Anchor-based 21 . 56
Anchor-based methods involve comparing a patient's change score with another 57 measure of clinically relevant change 24 . In this method, an external criterion of change is 58 compared with another measure of change. An example of external criterion may be the 59 change perceived by the patient or clinician 16, 25 (e.g. self-perceived improvement in walking 60 abilty). The other measure of change used for comparison is usually an objective data, such as 61 walking distance. Anchor based methods have the advantage of being more clearly 62 understood because change are related to a clear clinical observation 26 . This helps to 63 determine that a change is considered important to the patient, physician or researcher, and 64 even the health care authorities or society at large 27 . 65
Distribution-based methods, such as the standard error of the measure (SEM) 28 and 66 the effect size 29 , are built on the statistical and psychometric properties of the measure in a 67 population. Concurrent use of the two approaches is recommended to evaluate the effects of 68 the methodology on the final value 30 . 69 hal-00702219, version 1 -4 Jun 2012 insufficiency; symptomatic lower limb artery disease; severe renal insufficiency; and any 94 associated deficiency such as severe orthopaedic troubles limiting use of the lower limbs and 95 that were more limiting to effort than the cardiac disease itself. 96
Protocol 97
All patients received an 8-week cardiac rehabilitation program that included two 98 components: 99 -Personalised training tailored on the basis of the results of a stress test, performed on 100 treadmill using the Bruce modified protocol 34 , before entering the rehabilitation programme 101 41 , and individualized on the basis of preliminary physical activity habits, determined using 102 the Dijon physical activity score questionnaire 11 . The training intensity was prescribed at a 103 target heart rate (HR) zone derived from the maximal HR at the end of the stress test.It was 104 calculated using the Karvonen formula 35 as follows: training HR = rest HR + 75% (max HR 105 -rest HR). During training sessions, Borg scale with level 6 to 20 was also used 36 . The 106 target was set between 13 and 15. 107 -Individual and group educational interventions based on the patient's risk factors 37 . 108
The training program was in line with the latest recommendations in the field [37] [38] [39] , 109
and consisted of one-and-a-half-hour sessions, 3 days a week over 8 weeks. In order to study inter-observer agreement between the patient and his therapist, the 126 same question was asked to the physiotherapist supervising the patient's training, using the 127 same 9-level scale. All ratings were completed before giving the result of the tests to ensure 128 that both participants and clinicians were blinded to the performance, as recommended for the 129 assessment of change in subjects in MCID studies 15 . 130
During the walk-tests, patients wore a telemetric device (Teleguard, GE Medical 131 Systems, Denmark). Blood pressure was measured before and immediately after each test in 132 the left arm using a standard cuff mercury sphygmomanometer. Patients were also asked to 133 rate their dyspnea on a Borg scale at the end of each test, and any clinical symptoms such as 134 angina were recorded. Both walk tests were supervised by a physiotherapist blinded to the 135 stress-test results and to the training group of the patient. 136
The 6MWT was performed on a 50-meter unobstructed path. The patients were 137 instructed to walk at a self-selected pace from one end of the path to the other and back, in 138 order to cover as much distance as they could during the allotted time. The time was called 139 out every 2 minutes. Standard encouragement at 30-second intervals was provided. Slowing 140 down and stopping to rest were permitted. At the end of 6 minutes, the total distance walked 141 hal-00702219, version 1 -4 Jun 2012 in meters (m) was measured. These technical aspects are in line with the American Thoracic 142
Society recommendations for the 6-minute walk test 40 . 143
The 200-meter fast walk test consisted of walking twice up and down the 50-m long 144 path in the hospital corridor as fast as possible, without running. Standard encouragement was 145 provided at mid-distance. Slowing down and stopping to rest were permitted. The time taken 146 to perform the test was measured in seconds 7, 11 . 147
148

Statistical Analyses 149
Change in walking distance (for the 6MWD) and in time (for the ) were expressed as 150 an absolute distance or time, by substracting the initial result from the discharge result. 151
For the anchor-based approach, patients were dichotomized based on their self 152 assessment of clinical change. A cutoff of 2 (slightly better, meaningful) was used to identify 153 patients who achieved an MCID (score  2) from those who did not (score <2). As previously 154 described, the mean score change for the smallest meaningful change (i.e.  2) was taken as 155 the MCID for both walk tests 41, 42 . Then, the means of those subjects who achieved an MCID 156 were compared with those who did not using a one-way ANOVA. The positive predictive 157 value (PPV), negative predictive value (NPV), sensitivity and specificity for change in the 158 6MWD and in 200MFWTT were calculated and a Receiver Operating Characteristic (ROC) 159 curve obtained. Given the objective of this work, i.e. to estimate the minimal improvement in 160 the 6MWD or in the 200MFWTT that would lead the patient to be satisfied with his outcome, 161 we chose to consider PPV and NPV rather than sensitivity and specificity to identify the 162 This analysis was repeated with patients dichotomized according to their 164 physiotherapist's assessment of clinical change, in order to identify the MCID from the 165 therapist's point of view. The same cutoff of 2 (slightly better, meaningful) was used to 166 distinguish between patients who achieved an MCID and those who did not. 167
Concerning the distribution-based methods, we used the SEM to estimate the MCID. 168
The SEM is defined as 1(1-r), where 1 is the baseline standard deviation and r is the 169 test-retest reliability. One SEM is supposed to be a close approximation of the MCID 28 . The 170 intraclass correlation coefficients used for test-retest reliability were calculated from data of a 171 previous study 7 , and were set at 0.71 for the 6-MWT and 0.87 for the 200-MFWT. 172
Agreement between the ratings of patients and physiotherapists was studied using 173
Cohen's κ correlation coefficient. Coefficients from 0 to 0.4 reflect a weak association, 0.4 -174 0.75 a moderate association, and above 0.75 a strong association 43 . 175 Improvement in maximal exercise capacity between patients achieving MCID and 176 those who did not were compared using a Student t-test, and correlations between 177 improvement in 6MWD and improvement in maximal exercise capacity were tested using 178
Pearson correlation coefficient. 179
Data were recorded using Excel software for Windows, and statistical analysis was 180 performed using NCSS 2004 for Windows. The threshold for significance was set at 181 p<0.05. 182
Sample Size 183
As walk tests are usually performed only at the beginning of the rehabilitation program and at 184 discharge, we could not calculate an estimated sample size based on the evolution of 185 performance in tests repeated every 2 weeks. According to the latest studies concerningMCID in the 6MWD in COPD and post-stroke functional measures 41, 42, 44 , and anticipating a 187 10% dropout from the program, we initially planned to include 80 patients. and the 200MFWT were 14.9 ± 0.8 and 16 ± 0.9 before, and 14.6 ± 0.9 and 16.1 ± 1 after, 203 respectively. All patients significatively improved maximal exercise capacity from 7.2 ± 1.7 204 METS at baseline to 9 ± 2.1 METs at the end of the training period (mean improvement 25 ± 205 13.8% %, p<0.01), without significative change in the maximal heart rate (121.2 ± 13. (table 2, B) . 235
An MCID of -2 seconds corresponded to a sensitivity of 0.67 and a specificity of 0.14 (AUC : 236 0.4; 95% CI: 0.27 -0.53) (Figure 4) . 237
Concerning the physiotherapists' ratings, 58 patients were rated 2 and 21 rated <2. 238
The mean change in the 6MWD in the patients classified as improved by the physiotherapist 239 (2) was + 15.2 ± 4.6 meters, compared with -9.9 ± 7.6 meters in those who were classified 240 as stable or worsened (<2) ( figure 3, B) . The mean change in 200MFWTT in those judged as 241 improved was -1.3 ± 1.2 seconds, vs. + 1.04 ± 1 seconds in those judged little improved or 242 stable or worsened. There was a significant difference between the 2 groups for the 6MWD 243 (p< 0.01) whereas no significant difference was found for the 200-MFWT performance (p= 244
0.12). 245
The PPV and NPV, sensitivity and specificity for the 6MWD and the 200MFWTT 246 When considering patients who rated themselves <2, 16 were considered stable or 256 worsened by the physiotherapist (score < 2), and 23 were considered improved (score  2)(table). There was no significant difference between patients classified <2 and those classified 258  2 by the physiotherapist for either the 6MWD or the 200MFWTT (table 4) . Moreover, there 259 was also no significant difference in the HR variation between the 2 evaluations for the 2 260 groups (table 4) . 261 262
Distribution-Based Estimation of the MCID 263
When considering the patients' self assessment, the SEM for the 6MWD was 23 264 meters using the baseline standard deviation for the 6MWD and an intraclass correlation To our knowledge, this is the first study to evaluate the MCID for walk tests among 282 CAD patients. A previous study determined an MCID for the health status in patients with 283 heart disease, but considered health-related quality of life scores, and used a different 284 approach, based on a consensus reached by a panel of physicians 45 . Here, we used a patient 285 anchor specific to functional walking capacity. Our work is thus complementary, as walking 286 tests and quality of life questionnaires measure different constructs 46 . Indeed, changes in 287 walking performance should not be used to infer changes in health-related quality of life, 288 irrespective of whether the MCID is achieved. 289
The MCID of 25 meters for the 6MWD identified in this study is similar to that 290 recently reported by Holland et al. among patients with diffuse parenchymal lung disease 47 291 and COPD patients 44 . As in the latter study, we identified a threshold distance at which 292 patients can identify clinical change using the ROC method, rather than using the average 293 distance associated with clinical change in a group of patients. Using this cutoff, the positive 294 predictive value was 0.9. This means that, when patients improve their 6MWD by 25 meters, 295 there is a 90% chance that they will feel a real improvement in their walking performance. 296
This was also associated with a specificity of 0.92, and a sensitivity of 0.55, meaning that 297 when patients do perceive a clinical change, there is a 55% chance that their walking capacity 298 has improved by more than 25 m. 299
Unlike the study of Holland et al. among COPD patients 44 , we did not find a 300 difference in the absolute change in 6MWD depending on the baseline walking distance. This 301 might be due to the difference in the sample, as our patients were younger, and showed a 302 higher baseline performance with less variability. This could also be due to the different 303
The majority of patients achieved the estimated MCID after rehabilitation (93%). We 305 chose to estimate the MCID between the 6th and 12th session, in order to avoid a skewed 306 distribution of perceived change scores (figure 1), and to minimize recall bias. Thus, at this 307 time, only 36% had achieved the MCID. This means that we had patients with change scores 308 greater than the calculated MCID values who considered their walking capacity unchanged or 309 worsened Conversely, other patients with change scores less than the calculated MCID 310 considered their walking capacity improved (score  2). Moreover, there was no difference in 311 maximal exercise capacity improvement between patients achieving MCID for the 6MWD 312 between the 2 nd and 3 rd evaluation and those who did not. This seems logical, as the 6MWT 313 remains a submaximal walk tests, and as the correlation between improvement in 6MWD and 314 maximal exercise capacity improvement was moderate, as previously reported 6 . Our MCID 315 values should thus be interpreted with caution, particularly when making judgments about 316 individual patients, and exercise capacity assessment remains the gold standard for prognosis. 317
Studies of retrospective change have shown that subjects tend to judge their 318 assessments of change based on their current condition, remembering backwards in time from 319 that point rather than remembering their initial condition and working forward 48 . Thus, 320 estimating perceived change every 6 to 8 sessions allowed us to minimize this bias, even 321 though this methodology is not as strong as would be a prognostic study of predicted change. 322
323
The estimation of the MCID for the 6MWD was different when determined by the 324 patient or the physiotherapist. Previous studies in other diseases concerning agreement 325 between patients' and clinicians' ratings of change showed inconsistent results, ranging from 326 poor 49, 50 to good 26 agreement. Physicians may have a skewed perspective on functional 327 change given the little time spent actually observing patients 51 . However, one could think 328 that other health professionals, such as physiotherapists, who are more familiar with the day-329 to-day functioning of patients, would have an estimation of clinical change closer to that ofpatients. This was not the case in our study, as there was poor agreement between change 331 assessed by patients and that assessed by physiotherapists (Cohen κ correlation coefficient = 332 0.17). For example, among patients who rated themselves <2, 16 were considered stable or 333 worsened by the physiotherapist (score < 2), and 23 were considered improved (score  2). 334
However, there was no significant difference between these 2 groups for the 6MWD (table 4) . 335
Physiotherapists may take into account many subjective (general appearance of the patient, 336 mood, other complaints, etc.) and objective data (total work on ergometers, HR during 337 training sessions) in their judgment, related to their own experience and history. Some of 338 these data were probably considered more important by the physiotherapist than by the 339 patients in interpreting the perception of clinical change. However, in our study, there was no 340 significant HR variation between the 2 nd and the 3 rd evaluation. This might not have affected 341 the change perceived by the physiotherapist. Future studies may include regression analyses 342 to identify the components of relevant clinical change for the therapist and the patient. 343
Our study failed to identify an MCID with satisfactory metrological qualities for the 344
200MFWT. The anchor-based method did not show a significant difference in means between 345 patients rating <2 and those rating  2. A 4.2-second improvement in the 200MFWTT was 346 determined as the MCID when using the distribution method. However, this finding has to be 347 interpreted very cautiously as the ROC method did not allow us to identify a threshold with 348 sufficient metrological qualities for a time improvement at which patients can identify a 349 clinical change. The 200MFWT test explores higher exercise intensities than does the 6MWT 350 7 . It could be harder for a patient to interpret his feelings during a test that is closer to his 351 maximal capacity. Indeed, the 6MWT is submaximal moderate exercise, approximately 352 corresponding to the first VT 6, 52 . Thus, it might be easier for patients to have a better 353 perception of their walking ability during this test, which may better reflect their daily 354 activities than the 200MFWT, which is more like running to catch a bus, for example. The200WFWT might be more useful as a tool to help design or assess high intensity 356 rehabilitation programs, such as interval training. 357
The sensitivity and specificity of tests are often used to choose a cutoff for the 358 significance of a clinical or biological variable. Here, we chose the PPV and NPV to identify 359 a meaningful cutoff for the MCID. Indeed, we chose these metrologic properties to find 360 answers to the question raised: will a patient who improves beyond the identified MCID 361 perceive a clinical change? Based on our results, with a 25-meter cutoff, we can affirm that in 362 this population, 90% of patients who improved their 6MWD by more than 25 meters 363 perceived a meaningful clinical change in their walking ability. Conversely, among patients 364 who improved by less than 25 meters, 66% did not perceive any change. The PPV is 365 influenced by the prevalence of the studied parameter in the population considered. However, 366 the anthropometric characteristics and baseline walk performance of our sample was quite 367 similar to that of other studies in the field 7, 9 . 368 By defining the threshold for clinically important change, we improve our ability to 369 interpret the effects of cardiac rehabilitation programs in routine clinical practice as well as in 370 randomized clinical trials that assess the effectiveness of interventions. Thus, an MCID 371 reference improvement of 25 meters for the 6MWD could serve as an explicit therapeutic goal 372 for rehabilitation or other therapeutic interventions that aim to improve walking ability and 373 participation levels for CAD patients. Indeed, a valid MCID for 6MWD improvement is 374 useful for the clinical interpretation of individual rehabilitation programs, but also the clinical 375 significance of intervention studies that may find statistical improvements in 6MWD but may 376 not achieve a clinically meaningful threshold. Moreover, sample size heavily influences the 377 statistical significance of an improvement in performance in a clinical trial. The clinically 378 interpretable effects of a training program on measurements of performance can be examined 379 according to standards of meaningful change by comparing the proportion of treatment andcontrol groups who achieve change and calculating the number needed to treat 53 . Finally, 381 sample size estimates are needed in the planning stage of research studies and should be based 382 on the ability to detect clinically significant levels of change. 383 384 385
Study Limitations 386
Our study in one cardiac rehabilitation department comprised a relatively small sample 387 of stable CAD patients and included very few women. Moreover, they all benefited from 388 standardized care during the acute phase, which may vary from one cardiology acute care 389 department to another. Thus, we cannot generalize our results to the whole population of 390 CAD patients. Future studies with larger sample sizes including patients with different 391 functional statuses are now needed to refine our estimates and to determine how MCID values 392 are affected by time since the MI, by the severity and/or clinical features of the initial MI, and 393 by the initial acute care procedure. 394
Even though we chose to assess the MCID at the period with the widest diversity in 395 degrees of self-perceived change, very few patients (4) reported a decline in walking ability. 396
This seems logical, given the well-known benefits of cardiac rehabilitation programs. Among 397 these 4 patients, only one really had a lower 6MWD (-5 meters). We were therefore unable to 398 assess whether the MCID for decline differed from the MCID for improvement, as has 399 previously been reported 54 . 400
Finally, only a small number or physical therapists participated in the 401 assessment of change, and all of these had specialized in cardiac rehabilitation. Future studies 402
should include more physiotherapists from multiple settings. 403
CONCLUSIONS 405
Our study provides the first estimates of a minimal clinically important difference, 406 approximately 25 meters, in performance at the 6-minute walk test in a CAD population. This 407 result supports the use of the 6-MWT during cardiac rehabilitation programs in CAD patients 408 after ACS , and will help practitioners and researchers interpret changes in the 6MWD in this 409 population. 
